Literature DB >> 51029

Daytime titers of testosterone, LH, estrone, estradiol, and testosterone-binding protein: acute effects of LH and LH-releasing hormone in men.

H R Nankin, R Pinto, D F Fan, P Troen.   

Abstract

Four normal 18-20 yr-old men were studied on 3 occasions, from 0830 h to 1500 h. The baseline for each study consisted of 3 or 4 measurements of the respective hormone obtained between 0830 and 0900 h. In the control studies mean testosterone (T) fell by 43% (P less than 0.01) during the final 30 min. The fall was gradual throughout the day and was significant by 1100 h (P less than 0.05). Administration of LH and LH-releasing hormone (LHRH) at 0900 h resulted in 9-fold (5 min) and 3-fold (30 min) higher concentrations of LH respectively. LH declined more slowly after LHRH. Titers of T rose to the 0830-0900 h mean 130 min after LH but were never significantly elevated; the occurrence of a significant drop in mean T was delayed for 70 min. After LHRH there was a nonsignificant 24% increase of the mean T followed by a slow decline; however, T did not fall significantly below the mean baseline level. In contrast, in 2 of the 4 subjects LHRH resulted in rises in T levels (P less than 0.05) above the basal titers. Testosterone-binding globulin (TeBG) mean titers showed no diurnal rhythm in the control studies. There were statistically significant elevations of mean TeBG 150 min after LH and 340 to 370 min after LHRH, as well as sustained increases during the final 30 to 210 min of 1 or 2 individuals in each group. The reason for these increases in TeBG is not presently known. Estrogen analyses performed in all studies on 2 of the subjects revealed: 1) afternoon titers of estrone were lower than baseline in all 6 studies, 2) there was no diurnal rhythm for estradiol in control studies, and 3) estradiol increased during the final 2.5 to 3 h after LHRH (P less than 0.01), but after LH it was not altered in 1 man and was lower in the other.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 51029     DOI: 10.1210/jcem-41-2-271

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Bioavailable Testosterone Linearly Declines Over A Wide Age Spectrum in Men and Women From The Baltimore Longitudinal Study of Aging.

Authors:  Elisa Fabbri; Yang An; Marta Gonzalez-Freire; Marco Zoli; Marcello Maggio; Stephanie A Studenski; Josephine M Egan; Chee W Chia; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-02-27       Impact factor: 6.053

2.  Testosterone and bioavailable testosterone help to distinguish between mild Cushing's syndrome and polycystic ovarian syndrome.

Authors:  M E Pall; M C Lao; S S Patel; M L Lee; D E Ghods; D W Chandler; T C Friedman
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

3.  Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men.

Authors:  G D Honda; L Bernstein; R K Ross; S Greenland; V Gerkins; B E Henderson
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

4.  The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring.

Authors:  B E Henderson; L Bernstein; R K Ross; R H Depue; H L Judd
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

5.  Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan.

Authors:  H Shimizu; R K Ross; L Bernstein; M C Pike; B E Henderson
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

6.  Adolescent endogenous sex hormones and breast density in early adulthood.

Authors:  Seungyoun Jung; Brian L Egleston; D Walt Chandler; Linda Van Horn; Nola M Hylton; Catherine C Klifa; Norman L Lasser; Erin S LeBlanc; Kenneth Paris; John A Shepherd; Linda G Snetselaar; Frank Z Stanczyk; Victor J Stevens; Joanne F Dorgan
Journal:  Breast Cancer Res       Date:  2015-06-04       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.